Slide 1: Cover letter to stock exchanges: Investor Presentation
Date: November 11, 2022 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543434 Scrip Symbol: SUPRIYA Dear Sir/Madam, Subject: Investor Pres
Slide 2: Earnings Presentation Q2FY23
Earnings Presentation Q2FY23
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Table of Contents
TABLE OF CONTENTS Sustainability 1. Q2 FY23 Highlights Growth 2. Company Overview 3. Historical Financial Performance Profitability 4. Future Outlook
Slide 5: Q2 FY23 Highlights
Q2 FY23 Highlights
Slide 6: CMD's Message
CMD’s Message “The first half of the financial year has been difficult for most sectors. However, we believe that this is only a temporary setback on the long road to development. In Q2FY23, we faced challenges in China market due to lockdowns in major cities. This has impacted our performance in th
Slide 7: Q2FY23 Highlights: Regional Performance
Q2FY23 Highlights (in INR mn) Revenue EBITDA PBT PAT Quarterly Rs. 1,122 mn Rs. 286 mn Rs. 274 mn Rs. 169 mn -25% YoY -65% YoY -65% YoY -71% YoY Business Mix Revenue Contribution – By Region Regional Performance 58% 47% Q2FY22 Q2FY23 29% 24% 13% 11% 8% 5% 2% 3% Asia Europe LAC North America Others 6
Slide 8: H1 & FY23 Highlights: Regional Performance
H1 & FY23 Highlights (in INR mn) Revenue EBITDA PBT PAT Quarterly Rs. 2,135 mn Rs. 598 mn Rs. 576 mn Rs. 421 mn -6% YoY -38% YoY -37% YoY -36% YoY Business Mix Revenue Contribution – By Region Regional Performance 63% H1FY22 H1FY23 32% 24% 23% 19% 12% 13% 8% 2% 4% Asia Europe LAC North America Other
Slide 9: Business Mix Revenue Contribution – By Therapy
Business Mix Revenue Contribution – By Therapy +12% Performance of the Therapeutic Areas Q2FY22 604 Q2FY23 540 528 The loss of sale due to continuous lockdown in China 137 122 111 89 63 85 57 27 (in INR mn) 23 Analgesic/Anesthetic Anti-histamine Vitamins Anti-Asthmatic Anti-allergic Anti-malarial 56
Slide 10: Profit & Loss Statement
Profit & Loss Statement Particulars (in INR mn) Q2 FY23 Q2 FY22 Y-o-Y Q1 FY23 Q-o-Q H1 FY23 H1 FY22 Y-o-Y Revenue from Operations 1121.7 1502.3 -25% 1,013.6 11% 2135.3 2271.8 -6% Cost of Materials Consumed 424.9 464.4 425.9 850.8 883.6 Changes in Inventories of Finished Goods and Work 44.0 -28.2 -75
Slide 11: Summary Statement of Assets and Liabilities
Summary Statement of Assets and Liabilities Particulars (in INR mn) Sep 22 Mar 22 Particulars (in INR mn) Sep 22 Mar 22 ASSETS EQUITY Non-current assets (i) Equity share capital 161.0 161.0 (i) Property, plant and equipment 1,821.4 1,824.7 (ii) Other equity 6,358.5 5,995.9 (ii) Right to Use Asset 55
Slide 12: Summary statement of Cashflow
Summary statement of Cashflow (in INR mn) Particulars (in INR mn) Sep 22 Sep 21 Cash Flow from Operating Activities Profit before Tax 575.6 917.0 Adjustment for Non-Operating Items 22.7 41.0 Operating Profit before Working Capital Changes 598.3 957.9 Changes in Working Capital -548.4 -613.2 Cash Gen
Slide 13: Company Overview
Company Overview
Slide 14: Business Overview
Business Overview Approved facility with Diversified operations Largest exporter of strong IP Niche product basket of Chlorpeniramine with presence in Maleate, Ketamine 38 APIs 86 countries Hydrochloride and Salbutamol Sulphate from India 15 DMFs with USFDA Manufacturing facility spread across React
Slide 15: Journey So Far
Journey So Far 2008 2009 2010 2011 2013 2014 Incorporation & Started CEP granted for IDL granted for COFEPRIS and USFDA approval conversion from production of Chlorphenamine Chlorphenamine KFDA granted; IDL a partnership Ketamine Maleate Maleate approval granted granted for firm to a public hydrochl
Slide 16: Company Differentiators
Company Differentiators Significant scale with leadership position across key & niche products Backward integrated business model Geographically diversified revenues with a global presence across 86 countries Advanced manufacturing and research and development capabilities Experienced senior managem
Slide 17: Significant Scale with Leadership Position In Key Products
Significant Scale with Leadership Position In Key Products Niche product offerings of 38 APIs with demonstrated ability to develop & scale-up production Leading exporter from India Presence for 10+ yrs in large & growing markets % share of exports from India (in terms of volume) Cetirizine Dihydroch
Slide 18: Backward Integrated Business Model
Backward Integrated Business Model Cost-competitive Supply Security Low Price Risk In-House Processes Structure Steady supply of Protection against Less Dependence On External Increasing margins essential raw materials market fluctuations Parties Integrated business model helped us grow revenue and
Slide 19: Diversified Geographic Presence
Diversified Geographic Presence • For key products we are seeing good traction in untapped regulated markets of North America • For Anaesthetic therapy 3 ANDA projects have been initiated and we are also working on ANDA projects for Anti Hypertensive and Vitamins Presence in 86+ Countries Across Glo
Slide 20: Diversified Revenues with Extensive Global Presence
Diversified Revenues with Extensive Global Presence Significant export presence, with low dependence on a specific geography … with customer concentration Export sales, as a % of revenue from operations Share of top 10 customers, as a % of revenue from operations 84.0% 62% 78.0% 79.0% 72.0% 52% 41%
Slide 21: Advanced Manufacturing and R&D Capabilities
Advanced Manufacturing and R&D Capabilities 4 7 597 KL 23,806 sq.mt. Manufacturing blocks Clean Reactor Land segregated therapy wise rooms capacity area ✓ Well delineated areas for R&D, quality control (chemical microbiology), quality assurance, dedicated areas for Scaled up Manufacturing Facilities
Slide 22: R&D Capabilities
R&D Capabilities Supported by R&D driven mindset 15* DMFs 3* Process Patent DSIR approved 9* Filed in India facility CEPs ✓ The Company has a DSIR approved R&D facility in Parshuram Lote, Maharashtra. ✓ Team of 26 scientists* primarily focused across the value chain of API process development ✓ Supr
Slide 23: Complex Chemistries & Reaction
Complex Chemistries & Reaction Focus on uniform manufacturing standards to achieve standardised product quality across markets High vacuum distillations … across varied class of reactions Ability to handle complex chemistries.. Cyclisation Grignard reaction ✓ Simple to highly complex chiral centre m
Slide 24: Recognized by Key Regulatory Bodies
Recognized by Key Regulatory Bodies 23 Q2 FY23 Earnings Presentation
Slide 25: Number of API's Under Pipeline
Number of API’s Under Pipeline API’s Under Pipeline Status USDMF’s 15 API’s Submitted CEP 9 API’s Granted USDMF 4 API Submission Under Progress CEP 1 API’s Assessment Under Progress CEP 4 API’s Submission Under Progress 24 Q2 FY23 Earnings Presentation
Slide 26: Awards & Accreditation
Awards & Accreditation 2009 2010 2016 2017 2019 Certificate of Excellence for Special Recognition National Award Export House for the Year for Export House for the Year for Outstanding Export outstanding Export Performance in for Research and Development 2015-16 awarded by Directorateof 2016-17 awar
Slide 27: Key Management Team
Key Management Team Satish Wagh Saloni Wagh Shivani Wagh Rajeev Jain Ashish Nayak Chairman & MD Whole-time Director Whole-time Director Chief Executive Officer Chief Financial Officer • B.Sc. from R.D National College and • B.Sc. from Parle Tilak Vidhyalaya • Bachelor’s degree in management • Master
Slide 28: Historical Financial Performance
Historical Financial Performance
Slide 29: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance Robust revenue growth … Capex Spend … and, focus on profitability EBITDA +23.7% 5,300.5 949 PAT +47.3% 2,140 3,911.9 1,732 3,195.4 1,518 2,801.0 1,236 1,063 670 734 179 394 53 94 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Return on Net Worth
Slide 30: Working Capital Break-up
Working Capital Break-up Inventory Receivables 206 73 68 172 63 53 130 76 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Payables Net Working Capital 78 79 194 196 75 49 105 67 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 No of days 29 Q2 FY23 Earnings Presentation
Slide 31: Summary Statement of Profit and Loss
Summary Statement of Profit and Loss Particulars (in INR mn) FY22 FY21 FY20 FY19 Total Revenue 5,300.5 3,912.4 3,195.4 2,801.0 Cost of Materials Consumed 1,988.3 1,405.7 1,523.8 1,460.7 Purchase of Traded Goods - - - - Changes in Inventories of Finished Goods and Work in Progress -30.3 -124.5 -139.0
Slide 32: Summary Statement of Assets and Liabilities
Summary Statement of Assets and Liabilities Particulars (in INR mn) Mar 22 Mar 21 Particulars (in INR mn) Mar 22 Mar 21 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1824.7 969.5 (i) Equity share capital 161.0 146.4 (ii) Right to Use Asset 58.0 14.7 (ii) O
Slide 33: Summary statement of Cashflow
Summary statement of Cashflow (in INR mn) Particulars (in INR mn) FY22 FY21 FY20 FY19 Cash Flow from Operating Activities Profit before Tax 2,072.4 1,673.9 962.3 571.0 Adjustment for Non-Operating Items 68.7 53.1 102.4 124.6 Operating Profit before Working Capital Changes 2,141.2 1,727.0 1,064.7 695
Slide 34: Future Outlook
Future Outlook
Slide 35: Future Outlook
Future Outlook Two new R&D centres • The future of company lies in R&D, initiated the process of setting up enhanced R&D facility 1. At Lote Parshuram to cater to lifecycle management and further backward integration projects (to be operational by Q3FY23) 2. At Ambernath to cater to new molecules an
Slide 36: Future Outlook
Future Outlook CMO/CDMO space • Company understands large scale special chemical manufacturing and has experience in handling hazardous complex process chemistry. • Initiated discussion with various companies ranging from big pharma to innovator companies to work as a partner for supplying products
Slide 37: Glossary
Glossary • API – Active Pharmaceutical Intermediates • DMF – Drug Master File • CEP – Certificate of Sustainability • USFDA – US Food And Drug Administration • EDQM – European Directorate for the Quality of Medicines & HealthCare • IDL – Import Drug Licence of China • KFDA – Korea Medical Device Reg
Slide 38: Thank You!
Thank You! Company : Investor Relations Advisors : Orient Capital (a division of Link Group) Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Ms. Rasika Sawant +91 95944 57518 Mr. Ashish Nayak – Chief Financial Officer rasika.sawant@linkintime.co.in cfo@supriyalifescience.com Mr. Rajesh Agrawa